Definiens, a provider of image analysis for digital pathology and diagnostics, has entered an agreement with Clarient Diagnostic Services, expanding the use of Definiens’ automated image analysis software and solutions in Clarient’s validated clinical applications for immunohistochemistry testing in breast cancer. Definiens’ Cognition Network Technology automatically classifies and quantitates key tissue features as part of Clarient’s Scope IA Platform offering.
 
“At Clarient, we combine world class pathology with innovation and our goal is to make a difference to physicians and their patients,” said Kenneth Bloom, MD, chief medical officer, Clarient Diagnostic Services. “Our work with Definiens will enable us to offer high quality, robust readouts with fast turnaround time. This means physicians will have better patient insights for diagnosis.”
 
“We are really pleased to work with Clarient on creating these validated applications for their routine clinical work. Running thousands of patient slides through our algorithms and seeing the computer-aided diagnosis in action is really gratifying,” said Thomas Heydler, chief executive officer of Definiens.